Related Experiment Video
Updated: Dec 29, 2025
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine
Nalinda B Wasala1, Shi-Jie Chen2,3, Dongsheng Duan1,4,5,6
1Department of Molecular Microbiology and Immunology, School of Medicine, The University of Missouri, Columbia, MO, USA.
Abstract:
Introduction: Duchenne muscular dystrophy (DMD) is an X-linked handicapping disease due to the loss of an essential muscle protein dystrophin. Dystrophin-null animals have been extensively used to study disease mechanisms and to develop experimental therapeutics. Despite decades of research, however, treatment options for DMD remain very limited.Areas covered: High-throughput high-content screening and precision medicine offer exciting new opportunities. Here, the authors review animal models that are suitable for these studies.Expert opinion: Nonmammalian models (worm, fruit fly, and zebrafish) are particularly attractive for cost-effective large-scale drug screening. Several promising lead compounds have been discovered using these models. Precision medicine for DMD aims at developing mutation-specific therapies such as exon-skipping and genome editing. To meet these needs, models with patient-like mutations have been established in different species. Models that harbor hotspot mutations are very attractive because the drugs developed in these models can bring mutation-specific therapies to a large population of patients. Humanized hDMD mice carry the entire human dystrophin gene in the mouse genome. Reagents developed in the hDMD mouse-based models are directly translatable to human patients.
Insights
Animal models are crucial for Duchenne muscular dystrophy (DMD) research. Nonmammalian models facilitate cost-effective drug screening, while patient-specific models advance precision medicine for DMD therapies.
Area of Science:
- Biomedical research
- Genetics
- Drug discovery
Background:
- Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder caused by the absence of dystrophin.
- Current treatment options for DMD are limited despite extensive research.
- Animal models are vital for understanding DMD and developing new therapies.
Purpose of the Study:
- To review animal models suitable for high-throughput screening and precision medicine in DMD research.
- To highlight the utility of nonmammalian and patient-specific models for therapeutic development.
Main Methods:
- Review of existing literature on animal models for Duchenne muscular dystrophy.
- Discussion of nonmammalian models (e.g., worm, fruit fly, zebrafish) for large-scale drug screening.
- Analysis of patient-specific models, including those with hotspot mutations and humanized mice, for precision medicine.
Main Results:
- Nonmammalian models have successfully identified promising lead compounds for DMD.
- Patient-specific models are being developed to create targeted therapies like exon-skipping and genome editing.
- Humanized hDMD mice offer direct translatability of findings to human patients.
Conclusions:
- Innovative animal models are essential for advancing Duchenne muscular dystrophy research.
- Nonmammalian models offer cost-effective screening, while patient-specific models pave the way for personalized DMD treatments.
- Further development and utilization of these models are critical for discovering effective DMD therapeutics.
